Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Down 6.6% – What’s Next?

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) traded down 6.6% during mid-day trading on Tuesday . The stock traded as low as $10.80 and last traded at $10.80. 711 shares traded hands during trading, a decline of 94% from the average session volume of 11,747 shares. The stock had previously closed at $11.56.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Santen Pharmaceutical presently has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The firm has a market cap of $3.43 billion and a price-to-earnings ratio of 0.10. The firm’s 50 day moving average price is $11.05 and its two-hundred day moving average price is $10.67.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.